ACHR/WS Market Analysis
News & Sentiment
32 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- —
- P/S (TTM)
- —
- EV/EBITDA
- —
Profitability & growth
- ROE (TTM)
- 0.0%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- —
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About ACHR-WS
Company profileAchieve Life Sciences, Inc. (Ticker: ACHR-WS) is a clinical-stage biopharmaceutical company focused on transforming the landscape of smoking cessation and nicotine addiction treatment through its lead candidate, cytisine. The firm aims to address a significant public health issue by enhancing nicotine replacement strategies to improve efficacy and patient outcomes. With a robust product pipeline and strategic partnerships, Achieve is well-positioned to capitalize on the growing demand for innovative cessation alternatives. Committed to scientific rigor and patient-centric approaches, Achieve…
Company profile
- HQ
- NONE
- Latest quarter
- —
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer